PharmAust Limited

ASX:PAA.AX

0.23 (AUD) • At close October 14, 2024
Bedrijfsnaam PharmAust Limited
Symbool PAA.AX
Munteenheid AUD
Prijs 0.23
Beurswaarde 111,926,052
Dividendpercentage 0%
52-weken bereik 0.068 - 0.535
Industrie Biotechnology
Sector Healthcare
CEO Dr. Michael Thurn Ph.D.
Website https://www.pharmaust.com

An error occurred while fetching data.

Over PharmAust Limited

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II

Vergelijkbare Aandelen

Respiri Limited logo

Respiri Limited

RSH.AX

0.081 AUD

Nova Eye Medical Limited logo

Nova Eye Medical Limited

EYE.AX

0.175 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)